ATAI Life Sciences N.V. (NASDAQ: ATAI)
$1.1700
-0.0500 ( -4.10% ) 945.8K
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Market Data
Open
$1.1700
Previous close
$1.2200
Volume
945.8K
Market cap
$195.87M
Day range
$1.1550 - $1.3490
52 week range
$1.0250 - $2.8500
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Mar 12, 2024 |
8-k | 8K-related | 18 | Feb 06, 2024 |
8-k | 8K-related | 14 | Jan 23, 2024 |
4 | Insider transactions | 1 | Jan 09, 2024 |
8-k | 8K-related | 13 | Jan 09, 2024 |
8-k | 8K-related | 47 | Jan 04, 2024 |
8-k | 8K-related | 18 | Jan 04, 2024 |
4 | Insider transactions | 1 | Nov 20, 2023 |
8-k | 8K-related | 13 | Nov 14, 2023 |
10-q | Quarterly Reports | 106 | Nov 14, 2023 |